BiotechTube

naquotinib

Phase 1Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-small Cell Lung Cancer (NSCLC)

Conditions

Non-small Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor (EGFR) Mutations

Trial Timeline

Mar 24, 2017 → Jun 19, 2017

NCT ID
NCT03082300

About naquotinib

naquotinib is a phase 1 stage product being developed by Astellas Pharma for Non-small Cell Lung Cancer (NSCLC). The current trial status is terminated. This product is registered under clinical trial identifier NCT03082300. Target conditions include Non-small Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor (EGFR) Mutations.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03082300Phase 1Terminated

Competing Products

20 competing products in Non-small Cell Lung Cancer (NSCLC)

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
77
NBTXR3NanobiotixPhase 1/2
36
pemetrexed + erlotinibEli LillyPhase 2
52
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
69
pemetrexed + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
pemetrexed + docetaxelEli LillyPhase 3
77
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
52
PemCarbo + Pem onlyEli LillyPhase 3
77
LY2875358 + ErlotinibEli LillyPhase 2
52
AdjuvantInsight Molecular DiagnosticsPre-clinical
15
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
77
Enzastaurin HCLEli LillyPhase 2
52
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 2
44
pemetrexed + gemcitabineEli LillyPhase 2
52
ALIMTA + CarboplatinEli LillyPhase 2
52
Tomivosertib + Pembrolizumab + PemetrexedeFFECTOR TherapeuticsPhase 2
44
Divarasib + Pembrolizumab + Pemetrexed + Carboplatin + CisplatinChugai PharmaceuticalPhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85